Results 81 to 90 of about 91,698 (296)

Transcriptional profiling of circulating extracellular vesicles from prebiopsy prostate cancer patients

Molecular Oncology, EarlyView.
RNA profiling of circulating extracellular vesicles (EVs) from blood samples of men undergoing prostate biopsy identifies transcripts associated with clinically significant prostate cancer. Integrative analysis with public tumor datasets links EV‐derived gene signatures to tumor stage and progression‐free survival, highlighting CASP3, XRCC2, and RIT1 ...
Stefan Werner, Pierre Tennstedt, Randi C. Pose, Christian Müller, Katharina Besler, Svenja Schneegans, Malik Alawi, Marie C. Roesch, Sven Peine, Desiree Bonci, Joanna Budna‐Tukan, Evi Lianidou, Catherine Alix‐Panabières, Derya Tilki, Klaus Pantel   +14 more
wiley   +1 more source

Indications and timing for genetic testing in ovarian cancer

Journal of Medical Science
Modern management of ovarian cancer (OC) relies on molecular diagnostics, with genetic testing playing a central role in therapeutic decisions. High-grade serous ovarian cancer (HGSOC) is frequently associated with mutations in the BRCA1 and BRCA2 genes,
Cezary Miedziarek, Maksymilian Markwitz, Michał Potograbski, Mikołaj Piotr Zaborowski   +3 more
doaj   +1 more source

The extent of error-prone replication-restart by homologous recombination is controlled by Exo1 and checkpoint proteins [PDF]

, 2014
Genetic instability, a hallmark of cancer, can occur when the replication machinery encounters a barrier. The intra-S phase checkpoint maintains stalled replication forks in a replication-competent configuration by phosphorylating replisome components ...
Ahn, Alabert, Bailis, Barlow, Bastia, Bester, Biswas, Boddy, Bolderson, Brown, Bähler, Carr, Carr, Casper, Cha, Chen, Cobb, Cobb, Codlin, Cotta-Ramusino, Dalgaard, De Piccoli, Durkin, El-Shemerly, Errico, Eydmann, Froget, Haghnazari, Halazonetis, Hartsuiker, Heichinger, Hu, Iraqui, Jia, Kai, Kaochar, Katou, Kolodner, Koundrioukoff, Krejci, Lambert, Lambert, Lambert, Lambert, Lambert, Lambert, Lee, Lindsay, Lisby, Lopes, Lucca, Maundrell, Meister, Mimitou, Miyabe, Miyabe, Mizuno, Mizuno, Moreau, Moreau, Moreno, Morin, Myung, Myung, Pandita, Raynard, Sabatinos, Segurado, Segurado, Smolka, Sogo, Stracker, Sun, Symington, Sørensen, Tercero, Tsubouchi, Watson, Zhu, Zou, Zubko   +80 more
core   +2 more sources

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source

Implementation of a stepwise process for somatic testing in patients with a new diagnosis of germline negative epithelial ovarian cancer

Gynecologic Oncology Reports
Objective: We sought to establish a process for increasing somatic tumor testing for patients with germline BRCA negative advanced stage epithelial ovarian cancer (EOC) and to gain insight into patients’ comprehension of their genetic testing. Methods: A
Casey L. Lawler, Sara M. Klennert, Kristin C. Cole, Karen S. Schaepe, Laura J. Ongie, Megan E. Grudem, Carolyn M. Klampe, Myra J. Wick, Vonda M. Wall, Sanjna Rajput, Clarissa L. Polen-De, Amanika Kumar   +11 more
doaj   +1 more source

Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer

Nature Communications, 2020
Defects in homologous recombination (HR) are found in some triple negative breast cancers, suggesting they may be sensitive to PARP inhibitors. In this phase II clinical trial of the PARP inhibitor rucaparib, changes in Ki67 levels did not correlate with
Neha Chopra, Holly Tovey, Alex Pearson, Ros Cutts, Christy Toms, Paula Proszek, Michael Hubank, Mitch Dowsett, Andrew Dodson, Frances Daley, Divya Kriplani, Heidi Gevensleben, Helen Ruth Davies, Andrea Degasperi, Rebecca Roylance, Stephen Chan, Andrew Tutt, Anthony Skene, Abigail Evans, Judith M. Bliss, Serena Nik-Zainal, Nicholas C. Turner   +21 more
doaj   +1 more source

Nuclear pore links Fob1‐dependent rDNA damage relocation to lifespan control

FEBS Open Bio, EarlyView.
Damaged rDNA accumulates at a specific perinuclear interface that couples nucleolar escape with nuclear envelope association. Nuclear pores at this site help inhibit Fob1‐induced rDNA instability. This spatial organization of damage handling supports a functional link between nuclear architecture, rDNA stability, and replicative lifespan in yeast.
Yamato Okada, Mina Iwaki, Kyosuke Hagiri, Rei Izumi, Masahiko Harata, Chihiro Horigome   +5 more
wiley   +1 more source

Analysis of homologous recombination deficiency in prostate cancer

Сибирский онкологический журнал
Background. Mutations in homologous recombination repair (HRR) genes (BRCA2, ATM, CHEK2, NBN, etc.) are found in 20–25 % of patients with metastatic prostate cancer (PC) and are an indication for prescription of PARP inhibitors.
A. G. Iyevleva, S. N. Aleksakhina, A. P. Sokolenko, E. A. Otradnova, A. S. Nikitina, K. A. Kashko, M. V. Syomina, N. S. Morozova, A. D. Shestakova, E. Sh. Kuligina, E. N. Imyanitov   +10 more
doaj   +1 more source

SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers

The Journal of Clinical Investigation, 2022
Poly(ADP-ribose) polymerase inhibitors (PARP inhibitors) have had an increasing role in the treatment of ovarian and breast cancers. PARP inhibitors are selectively active in cells with homologous recombination DNA repair deficiency caused by mutations ...
Zhen Lu, Weiqun Mao, Hailing Yang, Janice M. Santiago-O’Farrill, Philip J. Rask, Jayanta Mondal, Hu Chen, Cristina Ivan, Xiuping Liu, Chang-Gong Liu, Yuanxin Xi, Kenta Masuda, Eli M. Carrami, Meng Chen, Yitao Tang, Lan Pang, David S. Lakomy, George A. Calin, Han Liang, Ahmed A. Ahmed, Hariprasad Vankayalapati, Robert C. Bast Jr.   +21 more
doaj   +1 more source

Proteasomal degradation of intracellularly expressed Amblyomin‐X limits suicide gene therapy potential in melanoma cells

FEBS Open Bio, EarlyView.
This study explores the feasibility of expressing the antitumoral protein Amblyomin‐X through a suicide gene therapy approach and investigates its intracellular fate after gene delivery. Although the gene is efficiently expressed, melanoma cells rapidly degrade the Amblyomin‐X protein via proteasome activity.
Victor Dal Posolo Cinel, Carlos DeOcesano Pereira, Aline Ramos Maia Lobba, Melissa Regina Fessel, Ana Marisa Chudzinski‐Tavassi   +4 more
wiley   +1 more source